Sort   by:  
 Page size 
UnknownDual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs.
Not available
S-EPMC11536088 | biostudies-literature
UnknownKinase-templated abiotic reaction.
Not available
S-EPMC5615226 | biostudies-literature
UnknownDissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
Not available
S-EPMC3773763 | biostudies-literature
UnknownDifferential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Not available
S-EPMC5508078 | biostudies-literature
UnknownRational Design of Chemically Controlled Antibodies and Protein Therapeutics.
Not available
S-EPMC10278067 | biostudies-literature
UnknownSingle-molecule kinetic analysis of HP1-chromatin binding reveals a dynamic network of histone modification and DNA interactions.
Not available
S-EPMC5737501 | biostudies-literature
UnknownA rational blueprint for the design of chemically-controlled protein switches.
Not available
S-EPMC8486872 | biostudies-literature
UnknownStructure-based Design of Chimeric Influenza Hemagglutinins to Elicit Cross-group Immunity.
Not available
S-EPMC11870435 | biostudies-literature
ProteomicsFunctional proteomics defines differential signaling networks of the oncogenic kinases Bcr-Abl p210 and p185
The two major isoforms of the oncogenic Bcr-Abl tyrosine kinase, p210 and p185, are expressed upon the Philadelphia chromosome translocation. p210 is the hallmark of chronic myelogenous leukemia, whereas p185 occurs in the majority of B-cell acute lymphoblastic leukemia. Differences in protein-prote...
ORGANISM(S): Mus musculus (Mouse) 
2017-01-31 | PXD005149 | Pride
Leukemia Bcr-abl tyrosine kinase Interactome Silac Phosphoproteome 
UnknownComputational design of soluble and functional membrane protein analogues.
Not available
S-EPMC11236705 | biostudies-literature
Sort   by:  
 Page size